Citation Impact
Citing Papers
Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis
2017
MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis
2020
Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis
2017
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
2017
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease
2019
Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease
2021
Microbiota in health and diseases
2022 Standout
Non-alcoholic fatty liver disease
2017
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes
2022
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
2019
ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis
2021
Limitations of non-invasive tests for assessment of liver fibrosis
2020
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
2016
Non-alcoholic fatty liver disease – A global public health perspective
2018 Standout
Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin
2020 StandoutNobel
Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
2020
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice
2016
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
2022
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
2020
Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
2016
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
Mechanisms and disease consequences of nonalcoholic fatty liver disease
2021
Psoriasis
2021 Standout
Cell Biology of Ischemia/Reperfusion Injury
2012 Standout
NAFLD and diabetes mellitus
2016
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
2016
Genetic predisposition in nonalcoholic fatty liver disease
2017
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
2020
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
2020
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
2022
Non-alcoholic fatty liver disease
2021 Standout
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
2019 Standout
Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis
2018
Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
2019
Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials
2017
Mitochondrial fission in endothelial cells after simulated ischemia/reperfusion: role of nitric oxide and reactive oxygen species
2011
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
2017
Global burden of liver disease: 2023 update
2023 Standout
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
2019
Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease
2016
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
2018
Weight Loss Decreases Magnetic Resonance Elastography Estimated Liver Stiffness in Nonalcoholic Fatty Liver Disease
2016
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
2019
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Hepatocellular carcinoma
2022 Standout
Time-dependant protective effects of mangenese(III) tetrakis (1-methyl-4-pyridyl) porphyrin on mitochondrial function following renal ischemia-reperfusion injury
2010
The gut–liver axis and the intersection with the microbiome
2018
Regulation of Endothelial Function by Mitochondrial Reactive Oxygen Species
2011
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
2018
The Role of Oxidative Stress in Neurodegenerative Diseases
2015 Standout
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
2018 Standout
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
2021
A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
2020
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
2019
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
2017
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
2017 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non‐invasive diagnosis of advanced fibrosis in biopsy‐proven non‐alcoholic fatty liver disease: a prospective study
2015
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
2018
Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity
2016
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
2023 Standout
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
2020
Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers
2019
Reactive Oxygen Species in Metabolic and Inflammatory Signaling
2018 Standout
Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH Trials
2018
A review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials
2018
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Works of Jeffrey Cui being referenced
Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis
2016
Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study
2016
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
2016
Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study
2016
Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
2016
Pulsatile shear stress increased mitochondrial membrane potential: Implication of Mn-SOD
2009
947 Shared Genetic Effects Between Hepatic Steatosis and Fibrosis: A Prospective Twin Study
2016
Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy‐proven nonalcoholic fatty liver disease: A prospective study
2015
905 Non-Invasive Screening for NAFLD and Advanced Fibrosis in Diabetics in Primary Care Setting by MRI and MRE: A Prospective Pilot Study
2015